DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 202806/S-001

SUPPLEMENT APPROVAL
FULFILLMENT OF POSTMARKETING REQUIREMENTS

GlaxoSmithKline, LLC
Attention: Amita Chaudhari
Director, Global Regulatory Affairs
1250 South Collegeville Road; UP4400
Collegeville, PA 19426

Dear Ms. Chaudhari:

Please refer to your Supplemental New Drug Application (sNDA) dated June 26, 2013, received June 27, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Tafinlar (dabrafenib) Capsules, 50 mg and 75 mg.

We acknowledge receipt of your amendments dated December 13, 2013, December 23, 2013, and December 24, 2013.

This Prior Approval supplemental new drug application proposes revisions to Section 7 DRUG INTERACTIONS of the package insert to include updated drug interaction information based on the results from three drug interaction studies conducted under postmarketing requirements.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

FULFILLMENT OF POSTMARKETING REQUIREMENTS

This supplement contains (by cross-reference to your May 31, 2013 submission) your final study report for study BRF113771 for the following postmarketing requirements listed in the May 29, 2013 approval letter.

2044-8 **Drug-Drug Interaction Trial**

Complete a clinical trial evaluating the effects of repeat doses of oral ketoconazole on the repeat dose pharmacokinetics of dabrafenib in accordance with the FDA Guidance for Industry entitled "*Drug Interaction Studies – Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations"*. The results of this clinical trial should allow for a determination on how to dose Tafinlar (dabrafenib) capsules with regard to concomitant strong CYP3A4 inhibitors.

The timetable you submitted on April 4, 2013, states that you will conduct this trial according to the following schedule:

Final Report Submission: May 2013

2044-9 **Drug-Drug Interaction Trial**

Complete a clinical trial evaluating the effects of repeat doses of oral gemfibrozil on the repeat dose pharmacokinetics of dabrafenib in accordance with the FDA Guidance for Industry entitled "*Drug Interaction Studies – Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations"*. The results of this clinical trial should allow for a determination on how to dose Tafinlar (dabrafenib) capsules with regard to concomitant strong CYP2C8 inhibitors.

The timetable you submitted on April 4, 2013, states that you will conduct this trial according to the following schedule:

Final Report Submission: May 2013

2044-10 **Drug-Drug Interaction Trial**

Complete a clinical trial evaluating the effects of repeat doses of Tafinlar (dabrafenib) capsules on the single dose pharmacokinetics of warfarin (CYP2C9 substrate) in accordance with the FDA Guidance for Industry entitled "*Drug Interaction Studies – Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations"*. The results of this clinical trial should allow for a determination on how to dose Tafinlar (dabrafenib) capsules with regard to concomitant sensitive CYP2C9 substrates and CYP2C9 substrates with a narrow therapeutic window.

The timetable you submitted on April 4, 2013, states that you will conduct this trial according to the following schedule:

Final Report Submission: May 2013

We have reviewed your supplement and your May 31, 2013 final study report submissions and conclude that the above requirements were fulfilled.

We remind you that there are postmarketing requirements **and** postmarketing commitments listed in the May 29, 2013, approval letter that are still open.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Norma Griffin, Regulatory Project Manager, at (301) 796-4255.

Sincerely,

{See appended electronic signature page}

Jeffrey Summers, M.D.
Deputy Director for Safety
Division of Oncology Products 2
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUZANNE G DEMKO on behalf of JEFFERY L SUMMERS
12/26/2013